Tanezumab

Osteoarthritis, Hip

Pfizermonoclonal_antibodyPhase 3Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

8 Active assets in the Osteoarthritis, Hip cohort.

Asset / Sponsor	Phase	Rating
Ropivacaine Poznan University of Medical Sciences	Phase 4	BBB
Dexasone Poznan University of Medical Sciences	Phase 4	BBB
Celecoxib Pfizer	Phase 4	BB
Intravenous Dexamethsone Poznan University of Medical Sciences	Phase 4	BB
Remimazolam Seoul National University Hospital	Phase 4	BB

View all 15 →

Same molecule, other indications

Tanezumab is also rated in:

cancer-related conditionDormant

BB

Indicative · Phase 3

64 / 100

metastatic carcinoma in the boneDormant

BB

Indicative · Phase 3

64 / 100

osteoarthritis, kneeDormant

B

Indicative · Phase 3

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.